CoChat

Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts

Open access
Hodgson, J. Graeme, Yeh, Ru-Fang, Ray, Amrita, Wang, Nicholas J., Smirnov, Ivan, Yu, Mamie, Hariono, Sujatmi, Silber, Joachim, Feiler, Heidi S., Gray, Joe W., Spellman, Paul T., Vandenberg, Scott R., Berger, Mitchel S., James, C. David · 2009 · Neuro-Oncology
Cited by 149

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Development of model systems that recapitulate the molecular heterogeneity observed among glioblastoma multiforme (GBM) tumors will expedite the testing of targeted molecular therapeutic strategies for GBM treatment. In this study, we profiled DNA copy number and mRNA expression in 21 independent GBM tumor lines maintained as subcutaneous xenografts (GBMX), and compared GBMX molecular signatures to those observed in GBM clinical specimens derived from the Cancer Genome Atlas (TCGA). The predominant copy number signature in both tumor groups was defined by chromosome-7 gain/chromosome-10 loss, a poor-prognosis genetic signature. We also observed, at frequencies similar to that detected in TCGA GBM tumors, genomic amplification and overexpression of known GBM oncogenes, such as EGFR, MDM2, CDK6, and MYCN, and novel genes, including NUP107, SLC35E3, MMP1, MMP13, and DDX1. The transcriptional signature of GBMX tumors, which was stable over multiple subcutaneous passages, was defined by overexpression of genes involved in M phase, DNA replication, and chromosome organization (MRC) and was highly similar to the poor-prognosis mitosis and cell-cycle module (MCM) in GBM. Assessment of gene expression in TCGA-derived GBMs revealed overexpression of MRC cancer genes AURKB, BIRC5, CCNB1, CCNB2, CDC2, CDK2, and FOXM1, which form a transcriptional network important for G2/M progression and/or checkpoint activation. Our study supports propagation of GBM tumors as subcutaneous xenografts as a useful approach for sustaining key molecular characteristics of patient tumors, and highlights therapeutic opportunities conferred by this GBMX tumor panel for testing targeted therapeutic strategies for GBM treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1215/15228517-2008-113

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 149

Metadata

Authors
Hodgson, J. G., Yeh, R.-F., Ray, A., Wang, N. J., Smirnov, I., Yu, M., Hariono, S., Silber, J., Feiler, H. S., Gray, J. W., Spellman, P. T., Vandenberg, S. R., Berger, M. S., & James, C. D.
Venue
Neuro-Oncology
Published
2009-10-01
Volume
11
Issue
5
Pages
477-487
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2105005481
Cited by
149
References
6
FWCI
5.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. https://app.cochat.ai/papers/10.1215/15228517-2008-113
The paper
Hodgson, J. G., Yeh, R.-F., Ray, A., Wang, N. J., Smirnov, I., Yu, M., Hariono, S., Silber, J., Feiler, H. S., Gray, J. W., Spellman, P. T., Vandenberg, S. R., Berger, M. S., & James, C. D. (2009). Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro-Oncology. https://doi.org/10.1215/15228517-2008-113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.